Publications éq.2

Publications 2015-2017 de l’équipe 2

  1. Hauguel-Moreau M, Boccara F, Boyd A, Salem JE, Brugier D, Curjol A, Hulot JS, Kerneis M, Galier S, Cohen A, Montalescot G, Collet JP, Silvain J. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Eur Heart J. 2017 Jan 8.
  2. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017 Jan 10.
  3. Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, Funck-Brentano C, Girard PM, Costagliola D, Cohen A, Guiguet M; on behalf the PACS-HIV investigators (Prognosis of Acute Coronary Syndrome in HIV-infected patients). Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. Am Heart J. 2017 Jan;183:91-101.
  4. Alexandre J, Saloux E, Chequel M, Allouche S, Ollitrault P, Plane AF, Legallois D, Fischer MO, Saplacan V, Buklas D, Labombarda F, Blanchart K, Salem JE, Nowoczyn M, Puddu PE, Manrique A, Parienti JJ, Milliez P. Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery: a prospective cohort study. J Hypertens. 2016 Dec;34(12):2449-2457.
  5. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther. 2016 Nov;167:38-47.
  6. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Inter-individual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2016 Nov 28.
  7. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrié D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S, Salem JE, Abtan J, Rousseau H, Collet JP, Vicaut E, Montalescot G; ANTARCTIC investigators.Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016 Oct 22;388(10055):2015-2022.
  8. Meddeb M, Carpentier W, Cagnard N, Nadaud S, Grillon A, Barthel C, De Martino SJ, Jaulhac B, Boulanger N, Schramm F. Homogeneous Inflammatory Gene Profiles Induced in Human Dermal Fibroblasts in Response to the Three Main Species of Borrelia burgdorferi sensu lato. PLoS One. 2016 Oct 5;11(10):e0164117.
  9. Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, Soubrier F. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J. 2016 Oct;48(4):1118-1126.
  10. Salem JE, El-Aissaoui M, Alazard M, Hulot JS, Aissaoui N, Le-Heuzey JY, Funck-Brentano C, Faisy C, Urien S. Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial TachyarrhythmiasClin Pharmacokinet. 2016 Aug;55(8):991-1002.
  11. Catapano AL, Graham I, De Backer G, Wiklund O, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS )Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)Eur Heart J. 2016 Aug 27.
  12. Stillitano F, Turnbull IC, Karakikes I, Nonnenmacher M, Backeris P, Hulot JS, Kranias EG, Hajjar RJ, Costa KD. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J. 2016 Jul 22.
  13. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Influence of steroid hormones on ventricular repolarizationPharmacol Ther. 2016 Jul 22.
  14. Abehsira G, Bachelot A, Badilini F, Koehl L, Lebot M, Favet C, Touraine P, Funck-Brentano C, Salem JE. Complex influence of gonadotropins and sex steroid hormones on QT interval duration. J Clin Endocrinol Metab. 2016 May 11.
  15. Lenuzza N, Duval X, Nicolas G, Thévenot E, Job S, Videau O, Narjoz C, Loriot MA, Beaune P, Becquemont L, Mentré F, Funck-Brentano C, Alavoine L, Arnaud P, Delaforge M, Bénech H. Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. Eur J Drug Metab Pharmacokinet2016 Apr;41(2):125-38.
  16. Salem JE, El-Aissaoui M, Alazard M, Hulot JS, Aissaoui N, Le-Heuzey JY, Funck-Brentano C, Faisy C, Urien S. Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. Clin Pharmacokinet2016 Mar 5.
  17. Hulot JSIshikawa K, Hajjar RJ. Gene therapy for the treatment of heart failure: promise postponedEur Heart Journal, 2016 Feb 27.
  18. Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016 Feb;4(2):129-37.
  19. Dierick F, Hery T, Hoareau-Coudert B, Mougenot N, Monceau V, Claude C, Crisan M, Besson V, Dorfmüller P, Marodon G, Fadel E, Humbert M, Yaniz-Galende E, Hulot JS, Marazzi G, Sassoon D, Soubrier F, Nadaud S. Resident PW1+ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circ Res. 2016 Jan 12.
  20. Marchand A, Atassi F, Mougenot N, Clergue M, Codoni V, Berthuin J, Proust C, Trégouët DA, Hulot JS, Lompré AM. miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice. Biochim Biophys Acta. 2016.
  21. Sinilnikova OM, Dondon MG, Eon-Marchais S, et al. GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer. 2016; 16(1): 13.
  22. Girerd B, Montani D, Jaïs X, Eyries M, Yaici A, Sztrymf B, Savale L, Parent F, Coulet F, Godinas L, Lau EM, Tamura Y, Sitbon O, Soubrier F, Simonneau G, Humbert M. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J. 2016; 47(2): 541-52.
  23. Collet JP, Kerneis M, Hulot JS, O’Connor SA, Silvain J, Mansencal N, Brugier D, Abtan J, Barthélémy O, Vignalou JB, Payot L, Rousseau H, Vicaut E, Montalescot G; GAMMA investigators. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. Thromb Haemost. 2016; 115(2): 382-91.
  24. Collet JP, Funck-Brentano C, Prats J, Salem JE, Hulot JS, Guilloux E, Hu MY, He K, Silvain J, Gallois V, Brugier D, Anzaha G, Galier S, Nicolas N, Montalescot G. Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. Am J Cardiovasc Drugs. 2016; 16(1): 43-53.
  25. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016 37:67-119.
  26. Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet JP, Delaney JT,Hulot JS, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MS. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2015.
  27. Machado RD, Southgate L, Eichstaedt CA, Aldred MA, Austin ED, Best DH, Chung WK, Benjamin N, Elliott CG, Eyries M, Fischer C, Gräf S, Hinderhofer K, Humbert M, Keiles SB, Loyd JE, Morrell NW, Newman JH, Soubrier F, Trembath RC, Viales RR, Grünig E. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Hum Mutat. 2015; 36(12): 1113-27.
  28. Decouture B, Dreano E, Belleville-Rolland T, Kuci O, Dizier B, Bazaa A, Coqueran B, Lompre AM, Denis CV, Hulot JS, Bachelot-Loza C, Gaussem P. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood. 2015; 126(15): 1823-30.
  29. Knauer MJ, Diamandis EP, Hulot JS, Kim RB, So DY. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time? Clin Chem. 2015; 61(10): 1235-40.
  30. Collet JP, Hulot JS, Cuisset T, Rangé G, Cayla G, Van Belle E, Elhadad S, Rousseau H, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC investigators. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol. 2015; 71(11): 1315-24.
  31. Jeziorowska D, Korniat A, Salem JE, Fish K,Hulot JS. Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases. Expert Opin Biol Ther. 2015; 15(10): 1399-409.
  32. Simon N, Finzi J, Cayla G, Montalescot G, Collet JP,Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015; 71(9): 1059-66.
  33. Aimé A, Coulet F, Lefevre JH, Colas C, Cervera P, Flejou JF, Lascols O,Soubrier F, Parc Y. Somatic c.34G>T KRAS mutation: a new prescreening test for MUTYH-associated polyposis? Cancer Genet. 2015; 208(7-8): 390-5.
  34. Rapti K, Stillitano F, Karakikes I, Nonnenmacher M, Weber T,Hulot JS, Hajjar RJ. Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev. 2015; 2: 14067.
  35. Claude C, Mougenot N, Bechaux J, Hadri L, Brockschnieder D, Clergue M, Atassi F, Lompré AM,Hulot JS. Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. Mol Ther Methods Clin Dev. 2015; 2: 14065.
  36. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, Kong CW, Rushing S, Hansen J, Ceholski D, Kolokathis F, Kremastinos D, Katoulis A, Ren L, Cohen N, Gho JM, Tsiapras D, Vink A, Wu JC, Asselbergs FW, Li RA,Hulot JS, Kranias EG, Hajjar RJ. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015; 6: 6955.
  37. Garnier S, Hengstenberg C, Lamblin N, Dubourg O, De Groote P, Fauchier L, Trochu JN, Arbustini E, Esslinger U, Barton PJ, Meder B, Katus H, Frese K, Komajda M, Cook SA,Isnard R, Tiret L, Villard E, Charron P. Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. Int J Cardiol. 2015; 189: 105-7.
  38. Huertas A, Tu L, Thuillet R, Le Hiress M, Phan C, Ricard N,Nadaud S, Fadel E, Humbert M, Guignabert C. Leptin signalling system as a target for pulmonary arterial hypertension therapy. Eur Respir J. 2015; 45(4): 1066-80.
  39. Kuchenbaecker KB, Ramus SJ, Tyrer J, et al; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015; 47(2): 164-71.
  40. Girerd B, Coulet F, Jaïs X, Eyries M, Van Der Bruggen C, De Man F, Houweling A, Dorfmüller P, Savale L, Sitbon O, Vonk-Noordegraaf A,Soubrier F, Simonneau G, Humbert M, Montani D. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest2015; 147(5): 1385-94.
  41. Carillion A, Feldman S, Jiang C, Atassi F, Na N, Mougenot N, Besse S, Hulot JS, Riou B, Amour J. Overexpression of cyclic adenosine monophosphate effluent protein MRP4 induces an altered response to β-adrenergic stimulation in the senescent rat heart. Anesthesiology. 2015; 122(2): 334-42.
  42. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015; 36(18): 1123-35a.
  43. Saliba Y, Keck M, Marchand A, Atassi F, Ouillé A, Cazorla O, Trebak M,Pavoine C, Lacampagne A,Hulot JS, Farès N, Fauconnier J, Lompré AM. Emergence of Orai3 activity during cardiac hypertrophy. Cardiovasc Res. 2015; 105(3): 248-59.
  44. Salem JE, Sabouret P,Funck-Brentano C, Hulot JS. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol2015; 29(1): 10-20.
  45. Sassi Y, Ahles A, Truong DJ, Baqi Y, Lee SY, Husse B,Hulot JS, Foinquinos A, Thum T, Müller CE, Dendorfer A, Laggerbauer B, Engelhardt S. Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin Invest2014; 124(12): 5385-97.
  46. Friedrich FW, Reischmann S, Schwalm A, Unger A, Ramanujam D, Münch J, Müller OJ, Hengstenberg C, Galve E, Charron P, Linke WA, Engelhardt S, Patten M, Richard P, van der Velden J, Eschenhagen T,Isnard R, Carrier L. FHL2 expression and variants in hypertrophic cardiomyopathy. Basic Res Cardiol2014; 109(6): 451.
  47. Korostelev M, Bihan K, Ferreol L, Tissot N,Hulot JS,Funck-Brentano C, Zahr N. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Pharm Biomed Anal. 2014; 100: 230-5.
  48. Hajjar RJ,Hulot JS. Modeling CVD in human pluripotent cells by genome editing. J Am Coll Cardiol2014; 64(5): 460-2.